ABL Diagnostics Targets a Growth of +76.5% by 2026
The molecular diagnostics company announced on Monday a major acceleration in its growth, driven by the technological integration completed in 2025 and the full deployment of its exclusive distribution agreements. This leap of +76.5% represents a historic scale-up according to the management.
Acceleration in Kits and Reagents, Driven by the UltraGene Range
The kits and reagents segment crosses a new threshold with a target growth of 82.9% to reach €5.8M. This dynamic is based on two distinct drivers. The UltraGene range (syndromic qPCR tests, from the acquisition of Fast Track Diagnostics) shows an exceptional growth of 353.5% to €1.6M. The company's historic activity in HIV resistance testing, a recurring foundation of the company, maintains a robust momentum with a projected increase of 132.0% to €3.9M.
These two product lines embody the strategy of technological integration initiated the previous year and confirm the viability of the company's business model positioned as a global player in in vitro diagnostics.
Distribution Agreements Account for More Than Half of the Growth
The services and other segment sees its revenues nearly double with a target of €5.3M (+93.0%). The two exclusive distribution agreements established in 2025 deploy their full potential over a complete year. CDL Pharma (clinical research support activities) contributes €2.5M (growth of 289.7% on a comparable basis). Vela Diagnostics (commercial activities initiated in the second half of 2025) generates €1.6M with a growth of 457.2%. The software and solutions segment modestly progresses by 14.6% to €1.2M, supported by the resilience of the Nadis hospital software, which jumps by 117.2%.
In total, these three segments consolidate an unequal growth profile: while kits drive the increase, distribution agreements now constitute the second major contributor.
